Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Glutamic Acid Inhibits Bone Degradation: Prof. Moriyama
September 18, 2006
- Janssen to Upgrade MRs in Oncology, CNS
September 18, 2006
- FDA Reviewing Regulation on Emergency Research Without Informed Consent
September 18, 2006
- JRCS Considers Joint Purchase of Drugs
September 18, 2006
- R&D NEWS IN BRIEF
September 18, 2006
- BUSINESS NEWS IN BRIEF
September 18, 2006
- New System Automatically Prepares Tissue Sections: Kurabo
September 18, 2006
- Direct Price Bargaining between Makers and Med. Institutions
September 18, 2006
- MEDICAL DEVICE NEWS IN BRIEF
September 18, 2006
- Industry, JPA Oppose Korosho's Discussion Proposal on NHI Pricing and Revision Frequency
September 18, 2006
- NEW PRODUCTS
September 18, 2006
- Key Points of Discussion on the NHI Pricing Criteria and the Frequency of NHI Price Revisions
September 18, 2006
- Towa Pharmaceutical Begins Business with Suzuken Nationwide
September 18, 2006
- Chuikyo Approves NHI Price Listing of 13 API/20 Products
September 18, 2006
- Errorneous Medical Bills Remain at High Levels
September 18, 2006
- Korosho Drafting New Vision for the Pharmaceutical Industry
September 11, 2006
- Unapproved CO Monitor Recalled
September 11, 2006
- BUSINESS NEWS IN BRIEF
September 11, 2006
- MEDICAL DEVICE NEWS IN BRIEF
September 11, 2006
- SELF-MEDICATION NEWS IN BRIEF
September 11, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…